Jade Biosciences, Inc. (JBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0080642061
Jade Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -113.54 m USD |
| EBIT | -127.35 m USD |
| Net income | -127.41 m USD |
| Diluted EPS – continuing operations | -3.19 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
More stocks
- Joeone Co Ltd (601566.SS)
- Green Plains Inc. (GPRE)
- Savara Inc (SVRA)
- Orchid Island Capital, Inc. (ORC)
- Gansu Yasheng Industrial Group Co Ltd (600108.SS)
- Zhejiang JW Precision Machinery Co.Ltd (300984.SZ)
- Shanghai Hajime Advanced Material Technology Co. Ltd. (301000.SZ)
- Aussie Broadband Ltd (ABB.AX)
- EST Tools Co Ltd (300488.SZ)
- Mongolian Mining Corp (975.HK)
- Hippo Holdings Inc. (HIPO)
- State Power Rixin Technology Co. Ltd. (301162.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.